SARS-CoV-2 N Protein Targets TRIM25-Mediated RIG-I Activation to Suppress Innate Immunity.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
23 07 2021
Historique:
received: 22 06 2021
revised: 19 07 2021
accepted: 22 07 2021
entrez: 28 8 2021
pubmed: 29 8 2021
medline: 11 9 2021
Statut: epublish

Résumé

A weak production of INF-β along with an exacerbated release of pro-inflammatory cytokines have been reported during infection by the novel SARS-CoV-2 virus. SARS-CoV-2 encodes several proteins able to counteract the host immune system, which is believed to be one of the most important features contributing to the viral pathogenesis and development of a severe clinical picture. Previous reports have demonstrated that SARS-CoV-2 N protein, along with some non-structural and accessory proteins, efficiently suppresses INF-β production by interacting with RIG-I, an important pattern recognition receptor (PRR) involved in the recognition of pathogen-derived molecules. In the present study, we better characterized the mechanism by which the SARS-CoV-2 N counteracts INF-β secretion and affects RIG-I signaling pathways. In detail, when the N protein was ectopically expressed, we noted a marked decrease in TRIM25-mediated RIG-I activation. The capability of the N protein to bind to, and probably mask, TRIM25 could be the consequence of its antagonistic activity. Furthermore, this interaction occurred at the SPRY domain of TRIM25, harboring the RNA-binding activity necessary for TRIM25 self-activation. Here, we describe new findings regarding the interplay between SARS-CoV-2 and the IFN system, filling some gaps for a better understanding of the molecular mechanisms affecting the innate immune response in COVID-19.

Identifiants

pubmed: 34452305
pii: v13081439
doi: 10.3390/v13081439
pmc: PMC8402637
pii:
doi:

Substances chimiques

Coronavirus Nucleocapsid Proteins 0
Receptors, Immunologic 0
Transcription Factors 0
Tripartite Motif Proteins 0
Interferon-beta 77238-31-4
TRIM25 protein, human EC 2.3.2.27
Ubiquitin-Protein Ligases EC 2.3.2.27
RIGI protein, human EC 3.6.1.-
DEAD Box Protein 58 EC 3.6.4.13

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Istituto di Ricerca Virologica Oretta Bartolomei Corsi
ID : 0027603

Références

Nature. 2007 Apr 19;446(7138):916-920
pubmed: 17392790
Clin Chim Acta. 2020 Jul;506:145-148
pubmed: 32178975
Antiviral Res. 2005 Feb;65(2):69-78
pubmed: 15708633
Viruses. 2014 Aug 07;6(8):2991-3018
pubmed: 25105276
Front Immunol. 2014 Jul 23;5:342
pubmed: 25101084
Microbiol Mol Biol Rev. 2008 Dec;72(4):672-85, Table of Contents
pubmed: 19052324
Semin Immunopathol. 2017 Jul;39(5):529-539
pubmed: 28466096
Cell Mol Immunol. 2014 Mar;11(2):141-9
pubmed: 24509444
Cell. 2020 May 28;181(5):1036-1045.e9
pubmed: 32416070
Nat Rev Immunol. 2020 Sep;20(9):537-551
pubmed: 32203325
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Infect Genet Evol. 2008 Jul;8(4):397-405
pubmed: 17881296
Lancet Respir Med. 2020 Jul;8(7):687-695
pubmed: 32386571
Curr Opin Pulm Med. 2014 May;20(3):233-41
pubmed: 24626235
Viruses. 2019 Oct 18;11(10):
pubmed: 31635238
J Biol Chem. 2007 Nov 2;282(44):32208-21
pubmed: 17761676
N Engl J Med. 2020 Mar 12;382(11):1070-1072
pubmed: 32050059
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
Emerg Microbes Infect. 2020 Dec;9(1):1418-1428
pubmed: 32529952
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Nat Rev Immunol. 2020 Jul;20(7):397-398
pubmed: 32457522
J Infect Dis. 2020 Jun 11;221(12):1940-1947
pubmed: 32318703
Int J Antimicrob Agents. 2020 Mar;55(3):105924
pubmed: 32081636
Science. 2006 May 12;312(5775):879-82
pubmed: 16690858
Adv Virus Res. 2018;100:163-188
pubmed: 29551135
Immunity. 2012 Jun 29;36(6):959-73
pubmed: 22705106
Virus Genes. 2011 Feb;42(1):37-45
pubmed: 20976535
J Virol. 2020 Jun 16;94(13):
pubmed: 32295922
Epidemiol Health. 2020;42:e2020006
pubmed: 32023775
Respirology. 2018 Feb;23(2):130-137
pubmed: 29052924
J Virol. 2017 Feb 14;91(5):
pubmed: 28077633
J Virol. 2017 Mar 29;91(8):
pubmed: 28148787
Nature. 2014 May 1;509(7498):110-4
pubmed: 24590070
JAMA. 2020 Apr 14;323(14):1406-1407
pubmed: 32083643
Chin Med J (Engl). 2020 May 5;133(9):1015-1024
pubmed: 32004165
Cell. 2010 Apr 16;141(2):315-30
pubmed: 20403326
J Med Virol. 2021 Apr;93(4):2177-2195
pubmed: 33095454
J Biol Chem. 2009 Jun 12;284(24):16202-16209
pubmed: 19380580
Cells. 2021 Mar 02;10(3):
pubmed: 33801464
N Engl J Med. 2020 Mar 19;382(12):1177-1179
pubmed: 32074444
Proc Natl Acad Sci U S A. 2008 Oct 28;105(43):16743-8
pubmed: 18948594
J Virol. 2015 Dec;89(23):11858-70
pubmed: 26378164
Immunity. 2000 Oct;13(4):539-48
pubmed: 11070172
Nat Rev Microbiol. 2016 Aug;14(8):523-34
pubmed: 27344959
Protein Cell. 2014 Dec;5(12):912-27
pubmed: 25311841
Nat Rev Microbiol. 2019 Mar;17(3):181-192
pubmed: 30531947
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Mol Cell. 2013 Sep 12;51(5):573-83
pubmed: 23993742
Viruses. 2020 Dec 30;13(1):
pubmed: 33396605
J Microbiol Immunol Infect. 2020 Jun;53(3):404-412
pubmed: 32173241
Antiviral Res. 2006 Nov;72(2):78-88
pubmed: 16820226
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Mol Cell. 2014 Aug 21;55(4):511-23
pubmed: 25018021
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Nat Rev Immunol. 2020 Jun;20(6):363-374
pubmed: 32346093
N Engl J Med. 2020 Mar 5;382(10):970-971
pubmed: 32003551
Science. 2003 May 30;300(5624):1399-404
pubmed: 12730501
Science. 2020 Aug 7;369(6504):718-724
pubmed: 32661059

Auteurs

Gianni Gori Savellini (G)

Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy.

Gabriele Anichini (G)

Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy.

Claudia Gandolfo (C)

Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy.

Maria Grazia Cusi (MG)

Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy.
"S. Maria delle Scotte" Hospital, Viale Bracci, 1, 53100 Siena, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH